Coronavirus (COVID-19) vaccination rates among adults who live in England, including estimates by socio-demographic characteristic and Standard Occupational Classification (SOC) 2020

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

The data source for this dataset is the NI Vaccine Management System (VMS). VMS holds vaccination reports for COVID-19 and influenza vaccines which were either administered in NI or to NI residents. This dataset is an aggregated summary of COVID-19 vaccinations recorded in VMS. It is effectively a day-by-day count of living people vaccinated by dose, age band (on the day that the dataset was extracted from VMS) and LGD of residence. Aggregated summary data from VMS is published daily to the NI COVID-19 Vaccinations Dashboard. This dataset is updated weekly and allows NI vaccination coverage to be included in the GOV.UK Coronavirus (COVID-19) in the UK dashboard.

1)How many claims have been made to the VDPS due to an adverse reaction to a covid vaccine to date? 2)How many claimants have been notified of an outcome? 3)How many claims have been successful? Please provide a breakdown of which vaccine were used in the claims awarded. 4)How many claims have been rejected / unsuccessful? 5)What are the reasons for claims being rejected (causation, not meeting 60% threshold, ineligible to claim.) Please provide numbers? Please provide a breakdown of which vaccine was used in the claims when causation was accepted. 6) Is it possible to give the conditions that have met the criteria e.g VITT, GBS?.’ 7) How many claims have been waiting over 12 months, 18 months for a decision? 8) How many of the successful claims involved a fatality? 9) How many requests for a mandatory reconsideration have been received? How many have been determined? Of those determined how many have been allowed/ refused? 10) How many appeals to the tribunal have been filed? What are the outcomes? 11) How many claims not involving a Covid vaccine have been received since the NHSBSA took over administering the scheme Nov 21? How many have been awarded, and how many have been rejected on failing the 60% disability criteria? Response All data as of 3 January 2024. All data relates to claims received by the NHS Business Services Authority (NHSBSA) and those transferred from the Department for Work and Pensions (DWP) on 1 November 2021. All figures provided for questions 1 to 11 relate to COVID-19 vaccines. Fewer than five Please be aware that I have decided not to release the full details where the total number of individuals falls below five. This is because the individuals could be identified, when combined with other information that may be in the public domain or reasonably available. This information falls under the exemption in section 40 subsections 2 and 3 (a) of the Freedom of Information Act (FOIA). This is because it would breach the first data protection principle as: a - it is not fair to disclose individual’s personal details to the world and is likely to cause damage or distress. b - these details are not of sufficient interest to the public to warrant an intrusion into the privacy of the individual. Please click the below web link to see the exemption in full. www.legislation.gov.uk/ukpga/2000/36/section/40 Breach of confidentiality Please note that the identification of individuals is also a breach of the common law duty of confidence. An individual who has been identified could make a claim against the NHSBSA for the disclosure of the confidential information. The information requested is therefore being withheld as it falls under the exemption in section 41(1) ‘Information provided in confidence’ of the Freedom of Information Act. Please click the below web link to see the exemption in full. www.legislation.gov.uk/ukpga/2000/36/section/41 Please note that following disclosure of FOI-01448, FOI-01491 and FOI-01559, we are unable to provide several of the figures requested. This is because of the small changes in figures. For example, a figure might have increased by fewer than five. This is likely to happen because of the frequency of requests for the same information – once a month or more. Links to previous FOI responses can be found at: https://opendata.nhsbsa.net/dataset/foi-01448

Includes: Patient demographics, Source Organisation, vaccination details and vaccine batch events. Its scope covers: Anyone vaccinated within England Anyone vaccinated in a Devoted Administration where this information is subsequently passed to England.

Settings include: hospital hubs - NHS providers vaccinating on site local vaccine services – community or primary care led services which could include primary care facilities, retail, community facilities, temporary structures or roving teams vaccination centres – large sites such as sports and conference venues set up for high volumes of people

Timescales for dissemination can be found under 'Our Service Levels' at the following link: https://digital.nhs.uk/services/data-access-request-service-dars/data-access-request-service-dars-process

Vaccination rates and odds ratios by socio-demographic group among people living in England.

This statistical report, co-authored with the UK Health Security Agency (UKSHA), reports childhood vaccination coverage statistics for England in 2022-23. Data relates to the routine vaccinations offered to all children up to the age of 5 years, derived from the Cover of Vaccination Evaluated Rapidly (COVER). Additional information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through UKHSA's ImmForm system.

Estimates of the risk of all-cause and cardiac death in the 12 weeks after vaccination or positive SARS-CoV-2 test compared with subsequent weeks for people aged 12 to 29 years in England using two sources of mortality data: ONS death registrations and deaths recorded in Hospital Episode Statistics. 8 December 2020 to 25 May 2022. Experimental Statistics.

Figures on coronavirus (COVID-19) vaccine uptake in school pupils aged 12 to 17 years attending state-funded secondary, sixth form and special schools, broken down by demographic and geographic characteristics, using a linked English Schools Census and National Immunisation Management System dataset. Experimental Statistics.

The number and percentage of Covid-19 fully vaccinated people by age band. Population estimates are based on National Immunisation Management Service counts.This dataset has been updated to reflect new age bandings and population figures provided in July 2022.This dataset now includes details of the Autumn Booster programme.Note on analysis:This datasets presents the proportion of the eligible population who have received all vaccinations they are entitled to. This is terms as a "Complete Dose". The number of vaccinations required to qualify as a complete dose differs by the age of the individual. The following scale is used to determine this:- Aged 5 - 15 - Dose 1- Aged 16 - 24 - Dose 1 & Dose 2- Aged 35 - 50 - Dose 1, Dose 2 & Booster- Aged 50+ - Dose1, Dose2, Booster & Autumn BoosterData is updated weekly.

the amount of people that have received vaccine damage payouts for the Sars cov2 (covid 19 ) vaccines How many people have submitted claims and have been rejected How many people have submitted claims which are currently pending. Response All data is as of 19 January 2023 to correspond with the initial FOI request (FOI 28850) with the exception of question 1. All data relates to claims received by the NHS Business Services Authority (NHSBSA) and those transferred from the Department for Work and Pensions (DWP) on 1 November 2021. All figures provided below relate to COVID-19 vaccinations: Question 1 As of 1 December 2022, 31 claimants have been notified they are entitled to a Vaccine Damage Payment. Fewer Than 5 Please be aware that I have decided not to release the exact number of awards, as the number of awarded claims between 1 December 2022 and your request on 15 January 2023 is fewer than 5. This is because the claimants could be identified, when combined with other information that may be in the public domain or reasonably available. This information falls under the exemption in section 40 subsections 2 and 3A (a) of the Freedom of Information Act. This is because it would breach the first data protection principle as: a) it is not fair to disclose claimant personal details to the world and is likely to cause damage or distress. b) these details are not of sufficient interest to the public to warrant an intrusion into the privacy of the claimant. Please click the below web link to see the exemption in full. https://www.legislation.gov.uk/ukpga/2000/36/section/40 Breach of Patient confidentiality Please note that the identification of claimants is also a breach of the common law duty of confidence. A claimant who has been identified could make a claim against the NHSBSA or yourself for the disclosure of the confidential information. The information requested is therefore being withheld as it falls under the exemption in section 41(1) ‘Information provided in confidence’ of the Freedom of Information Act. Please click the below web link to see the exemption in full. https://www.legislation.gov.uk/ukpga/2000/36/section/41 Question 2 633 submitted claims have been rejected Question 3 There are 2,840 claims currently being processed Please note that this request and our response is published on our Freedom of Information disclosure log at:

Flu vaccine uptake (percent) in at risk individuals aged 6 months to 65 years (excluding pregnant women), who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual Flu Letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 85 percent vaccine uptake in those aged 65 and over. Prior to this, the national vaccine uptake ambition was 75 percent, in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk, and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus are likely to fall outside the listed Read codes. Therefore, this data should not be used for GP payment purposes.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.

These data describe pneumococcal polysaccharide vaccine (PPV) uptake for the survey year, for those aged 65 years and over.RationaleVaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Pneumococcal disease is a significant cause of morbidity and mortality. Certain groups are at risk for severe pneumococcal disease, these include young children, the elderly and people who are in clinical risk groups2. Pneumococcal infections can be non invasive such as bronchitis, otitis media or invasive such as septicaemia, pneumonia, meningitis. Cases of invasive pneumococcal infection usually peak in the winter during December and January. The pneumococcal polysaccharide vaccine (PPV) protects against 23 types of Streptococcus pneumoniae bacterium. It is thought that the PPV is around 50 percent to 70 percent effective at preventing more serious types of invasive pneumococcal infection2.Since 1992 the 23 valent PPV has been recommended for people in the clinical risk groups and since 2003, the PPV vaccination programme has expanded to include immunisation to all those aged 65 years and over in England1This indicator was judged to be a valid and an important measure of public health and was therefore included in the public health outcomes framework. Inclusion of these indicators will encourage the continued prioritisation and evaluation and the effectiveness of the PPV vaccination programme and give an indication of uptake at an upper tier Local Authority level. The vaccination surveys measure the proportion of eligible people that have received PPV at any time and the proportion that received PPV during the previous year, providing an opportunity to assess the delivery of the immunisation programme11 Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2013 to March 2014 [online]. 2015 [cited 2015 Mar]. Available from URL: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates 2 Pneumococcal infections, NHS Choices [online]. 2013 [cited 2013 Dec]. Available from URL: http://www.nhs.uk/conditions/vaccinations/pages/pneumococcal-vaccination.aspxDefinition of numeratorUKHSA provided UTLA level data. Clinical commissioning group (CCG) data is available from https://www.gov.uk/government/collections/vaccine-uptake#ppv-vaccine-uptakeDefinition of denominatorNumber of adults aged 65 years and over. Data from 2013 to 2014 are now available at source at a local authority level. Data prior to 2013 to 2014 were collected at a PCT level and converted to LA level for inclusion in PHOF using the criteria as defined below:Denominators for local authorities are estimated from denominators for PCTs. Denominators for PCTs include all people registered with practices accountable to the PCT, and no data are available to provide resident-based figures. Denominators for local authorities are estimated as follows: (For local authorities that have exactly the same boundary as a PCT, the PCT figure is used as it is the only estimate available for the residents of the PCT and local authority. For local authorities whose boundary is contained wholly within a single PCT, but is not equal to the whole PCT, the LA denominator is estimated as a proportion of the PCT figure, with the exceptions of Isles of Scilly, City of London, Rutland, Cornwall, Hackney and Leicestershire (see below). For local authorities whose boundaries include all or part of more than one PCT, the local authority denominator is estimated by aggregating the appropriate proportions of the denominators for the PCTs whose boundaries include part of the local authority. The appropriate proportions in cases ii and iii are defined according to the resident population (in the appropriate age group) in the calendar year overlapping most of the period of the indicator value (or the most recent available): resident population by Lower Layer Super Output Area were extracted and used to calculate the population resident in every LA PCT overlapping block.To calculate the denominator, each LA PCT overlap is calculated as a proportion of the PCT resident population, and then multiplied by the denominator for the PCT. A LA may overlap several PCTs: the appropriate portions of all the PCTs’ denominators are aggregated to give the denominator estimate for the LA. Expressed as an equation the denominator is calculated as follows: DenominatorLA = ∑ (DenominatorPCT × n/N) summed over all PCTs overlapping the LA where: DenominatorLA = Estimated denominator in the LA n = Population resident in the LA-PCT overlapping block N = Population resident in the PCT DenominatorPCT = Denominator in the PCT For Isles of Scilly, City of London and Rutland, no indicator data are presented (prior to 2013 to 2014), as the local authority makes up a very small proportion of the PCT, and estimates for the LAs based on the PCT figures are unlikely to be representative as they are swamped by the much larger local authority within the same PCT. The estimates for Cornwall, Hackney and Leicestershire local authorities are combined data for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland respectively in order to ensure that all valid PCT data are included in the England total.Denominators for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland are not combined for the 2019 to 2020 annual local authority level data."CaveatsThe pneumococcal vaccine uptake collection is a snapshot of GP patients vaccinated currently registered at the time of data extraction. The proportion of GP practices who provided data for the surveys are available from the uptake reports. Data will exclude patients who have received the vaccine but have subsequently died, patients who have since moved, or patients that are vaccinated but have not had their electronic patient record updated by the time of data extraction. Data for local authorities prior to 2013 to 2014 have been estimated from registered PCT level indicators. While the majority of patients registered with practices accountable to a PCT tend to be resident within that PCT, there are, in some PCTs, significant differences between their resident and registered populations. Therefore the estimates for LAs may not always accurately reflect the resident population of the local authority (LA). Please note that the PCT response rate should be checked for data completeness as this will have a knock on effect to the LA values.

Does the performance of the EU compared to neighbouring countries affect popular support for the EU? Following the benchmarking approach, we argue that people compare the performance of their country inside the EU with that of a country outside the EU and, as a result of this comparison, form their attitudes towards the EU. The COVID-19 vaccine rollout in 2020 represents an ideal scenario to test this benchmarking expectation. While the pandemic challenged countries across the globe simultaneously, the speed at which governments launched their vaccination programs differed. The UK rolled out its vaccines weeks before EU countries, and we study whether this affected popular support for the EU. We conduct an Unexpected Event during Surveys Design (UESD) based on a Eurobarometer survey in the field when the first vaccine was administered in the UK. Our results show that the start of the COVID-19 vaccination in the UK led to a significant decrease in specific policy support for the EU, while there is no consistent evidence of change in diffuse support for the EU. Our article has important implications for understanding attitudes toward European integration and performance evaluations.

Estimates of the association between coronavirus (COVID-19) vaccination and self-reported long COVID in people infected prior to vaccination, using data from the UK Coronavirus Infection Survey.

The 3.5-million-word Victorian Anti-Vaccination Discourse Corpus (hereon VicVaDis) is intended to provide a (freely accessible) historical resource for the investigation of the earliest public concerns and arguments against vaccination in England, which revolved around compulsory vaccination against smallpox in the second half of the 19th century. It consists of 133 anti-vaccination pamphlets and publications gathered from 1854 to 1906, a span of 53 years that loosely coincides with the Victorian era (1837-1901). This timeframe was chosen to capture the period between the 1853 Vaccination Act, which made smallpox vaccination for babies compulsory, and the 1907 Act which effectively ended the mandatory nature of vaccination.

The Quo VaDis project applies the latest techniques for large-scale computer-aided linguistic analysis to discussions about vaccinations in public discourse, and specifically in: social media discussions in English, UK Parliamentary debates and UK national press reports. The goal is to arrive at a better understanding of pro- and anti-vaccination views, as well as undecided views, which will inform future public health campaigns.

The project will be based in the world-renowned ESRC Centre for Corpus Approaches to Social Science (CASS) at Lancaster University, which was awarded a Queen's Anniversary Prize for Higher and Further Education in 2015. An interdisciplinary project team will work in interaction with three main project partners: Public Health England, the Department of Health and Social Care and the Department for Digital, Culture, Media & Sport.

The World Health Organization's (WHO) list of top ten global health threats includes 'vaccine hesitancy' - 'a delay in acceptance or refusal of vaccines despite availability of vaccination services'. Vaccination programmes are currently estimated to prevent between 2 and 3 million deaths a year worldwide. However, uptake of vaccinations in 90% of countries has been reported to be affected by vaccine hesitancy. In England, coverage for all routine childhood vaccinations is in decline, resulting in the resurgence of communicable diseases that had previously been eradicated. In August 2019, the UK lost its WHO measles elimination status.

The reasons for vaccine hesitancy are complex, but they need to be understood in order to be addressed effectively. This project focuses on discourse because the ways in which controversial topics such as vaccinations are talked about both reflect and shape beliefs and attitudes, which may in turn influence behaviour. More specifically, vaccinations have been the topic of UK parliamentary debates since before the first Vaccination Act of 1840; they have been increasingly discussed in the UK press since the early 1990s; and anti-vaccination views in particular have been described as part of a complex network of 'anti-public discourses' which, in recent years, are known to be both spread and contested on social media.

This project will involve the analysis of three multi-million-word datasets: (1) English-language contributions to three social media platforms: Mumsnet, Reddit and Twitter since the inception of each platform - respectively, 2000, 2005 and 2006; (2) UK national newspapers since 1990; and (3) UK parliamentary debates since 1830. These datasets will be analysed in a data-driven fashion by means of the computer-aided methods associated with Corpus Linguistics - a branch of Linguistics that involves the construction of large digital collections of naturally-occurring texts (known as 'corpora') and their analysis through tailor-made software. A corpus linguistic approach makes it possible to combine in a principled way the quantitative analysis of corpora containing millions of words with the qualitative analysis of individual texts, patterns and interactions. In this way, we will identify and investigate the different ways in which views about vaccinations are expressed in our data, for example, through patterns in choices of vocabulary, pronouns, negation, evaluation, metaphors, narratives, sources of evidence, and argumentation. We will reveal both differences and similarities in pro- and anti-vaccination views over time and across different groups of people, particularly as they form and interact on social media.

Our findings will make a major contribution to an understanding of views about vaccinations both in the UK (via our parliamentary and news datasets) and internationally (via our social media datasets). Through the involvement of our Project Partners, as well as more general engagement activities, these findings will be used as evidence for the design of future public health campaigns about vaccinations.

Shingles vaccine coverage for adults of GP registered population turning 71 between 1 April to 31 March, and vaccinated by the following end of June.RationaleThe shingles vaccination programme was introduced to reduce the incidence and severity of shingles in those targeted by the programme by boosting individuals’ pre-existing VZV immunity. The shingles vaccine stimulates individual pre-existing immunity, which cannot be acquired naturally, so immunisation is required for protection.In 2010, the UK’s Joint Committee on Vaccination and Immunisation (JCVI) recommended that a herpes zoster (shingles) vaccination programme should be introduced for adults aged 70 years, with a catch-up programme for those aged 71 to 79 years.In April 2017, eligibility criteria for the shingles vaccination were revised so that adults become eligible for the routine programme on their 70th birthday and remain eligible until their 80th birthday. Following this change, from 2018 to 2019, vaccine coverage is measured in those aged 71 and is calculated as the total number of patients who turned 71 between 1 April and 31 March, and were vaccinated by the end of June, as a proportion of the number of patients that turned 71 years old between 1 April and 31 March.Prior to this (2013 to 2014 to 2017 to 2018), the vaccine was routinely offered to adults aged 70 years on 1 September of the programme year. Vaccine coverage was calculated as the total number of patients aged 70 on 1 September who had ever received the vaccination (numerator) as a proportion of the number of patients registered aged 70 years on 1 September (denominator) as of the following August.Due to the changes in the vaccination coverage collection described, data for this indicator are not comparable to the previous shingles indicator D06c: shingles vaccination coverage among 70-year-olds, available from 2013 to 2014 to 2017 to 2018.Reference:Shingles (herpes zoster): the green book, chapter 28.Definition of numeratorNumber of patients registered with a GP practice with 71st birthday within the financial year that received a shingles vaccination by the end of the June. The age and timing of the extraction for the numerator are different to the numerator describe in submissions prior to 2018 and 2019 in the D06c Population vaccination coverage: Shingles (70 years old) indicator. The numerators from these two indicators should not be compared.Definition of denominatorNumber of patients registered with a GP practice in each LA whose 71st birthday is within the financial year. The age and timing of the extraction for the denominator are different to the denominator describe in submissions prior to 2018 and 2019 in the D06c Population vaccination coverage: Shingles (70 years old) indicator. The denominators from these two indicators should not be compared.CaveatsAggregated GP practice level shingles vaccine coverage data is automatically uploaded via participating GP IT suppliers to the ImmForm website on a quarterly basis, and these data in turn are aggregated to LA level. The proportion of participating practices is currently at least 95 percentof all GP practices in England. Therefore, number of registered patients aged 71 years in each LA is based on participating practices only. Where less than 100 percent of practices in an LA participate the number of registered patients will not represent the true total in that LA and therefore vaccine coverage may not be truly representative of that LA.

Behaviour of fully vaccinated individuals not required to self-isolate after being in contact with a positive case of COVID-19, from the COVID Test and Trace Contacts Behavioural Insights Survey. Experimental Statistics.

This item has been replaced by the one which can be found at https://doi.org/10.7488/ds/2725 . ## # Abstract # Many livestock and increasingly human vaccines are leaky, blocking symptoms without preventing infection or onward transmission. Leakiness is concerning as it increases vaccination coverage required to prevent disease spread, and can promote evolution of increased pathogen virulence. Despite leakiness, vaccination may reduce pathogen load, affecting disease transmission dynamics. However, the impacts on post-transmission disease development and infectiousness in contact individuals are unknown. Here, we use transmission experiments involving Marek's disease virus in chickens to show that vaccination with a leaky vaccine substantially reduces viral load in both vaccinated individuals and unvaccinated contact individuals they infect. Consequently, contact birds are less likely to develop disease symptoms or die, show less severe symptoms when these are present, and shed less infectious virus themselves, when infected by vaccinated birds. These results highlight that even partial vaccination with a leaky vaccine can have unforeseen positive consequences in controlling the spread and symptoms of disease.